Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies
Language English Country United States Media print-electronic
Document type Journal Article, Observational Study, Research Support, Non-U.S. Gov't
PubMed
29793653
DOI
10.1016/j.clml.2018.04.003
PII: S2152-2650(17)31844-X
Knihovny.cz E-resources
- Keywords
- Czech Republic, MM, RMG, Survival, Treatment patterns,
- MeSH
- Survival Analysis MeSH
- Bortezomib therapeutic use MeSH
- Progression-Free Survival MeSH
- Lenalidomide therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Multiple Myeloma mortality pathology therapy MeSH
- Follow-Up Studies MeSH
- Prospective Studies MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Registries statistics & numerical data MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Thalidomide therapeutic use MeSH
- Stem Cell Transplantation * MeSH
- Age Factors MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- Names of Substances
- Bortezomib MeSH
- Lenalidomide MeSH
- Thalidomide MeSH
INTRODUCTION: Real-world data on patient outcomes and treatment patterns in multiple myeloma (MM) are limited. MATERIALS AND METHODS: The present noninterventional, observational, retrospective analysis of prospectively collected Czech patient medical record data from the Registry of Monoclonal Gammopathies estimated real-world outcomes in adults with a diagnosis of symptomatic MM made between May 2007 and June 2014. RESULTS: In total, 2446 patients had initiated first-line treatment. The median overall survival since the diagnosis (primary endpoint) was 50.3 months (95% confidence interval, 46.1-54.5 months) and decreased with each successive treatment line. A similar trend was observed for progression-free survival and the depth of response. In line with European guidelines and clinical practice, bortezomib-, thalidomide-, and lenalidomide-based regimens were most commonly used across all treatment lines (42.3%, 28.9%, and 18.4%, respectively). In the first line, bortezomib and thalidomide were used most often, with lenalidomide the most commonly used agent in the relapse setting (second to fourth lines). Exploratory analyses revealed that younger age (≤ 65 years), lower international staging system stage, and previous stem cell transplantation were associated with significant improvements in overall and progression-free survival, especially in the early treatment lines. CONCLUSION: The present study is the first analysis of Czech data from the Registry of Monoclonal Gammopathies, and it provides important insights into the real-world management of MM for physicians and healthcare providers.
Department of Clinical Hematology Hospital České Budějovice České Budějovice Czech Republic
Department of Hematology and Transfusion Medicine Hospital Pelhřimov Pelhřimov Czech Republic
Department of Hematology General Hospital Liberec Liberec Czech Republic
References provided by Crossref.org
